ResMed (NYSE:RMD) Analyst Rating Consensus

ResMed (NYSE:RMD) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 3.06 by 9 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold. 2 Analysts have rated it as strong sell.

Other Equity analysts have also commented on the company shares. Brokerage firm Macquarie upgrades its rating on ResMed (NYSE:RMD). The shares have been rated Neutral. Previously, the analysts had a Underperform rating on the shares. The rating by the firm was issued on April 28, 2016.

ResMed (NYSE:RMD): The mean estimate for the short term price target for ResMed (NYSE:RMD) stands at $56.2 according to 7 Analysts. The higher price target estimate for the stock has been calculated at $64 while the lower price target estimate is at $44.

ResMed (NYSE:RMD) rose 3.22% or 1.93 points on Tuesday and made its way into the gainers of the day. After trading began at $60.52 the stock was seen hitting $61.96 as a peak level and $60.32 as the lowest level. The stock ended up at $61.78. The daily volume was measured at 1,517,555 shares. The 52-week high of the share price is $61.96 and the 52-week low is $48.99. The company has a market cap of $8,675 million.

Shares of ResMed Inc. rose by 3.69% in the last five trading days and 7.22% for the last 4 weeks. ResMed Inc. is up 10.17% in the last 3-month period. Year-to-Date the stock performance stands at 16.28%.

ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.